The DOI matches its Crossref record; 366 of the 371 references it cites were found in a registry or an index.
EASL Clinical Practice Guidelines: Drug-induced liver injury
Abstract
Idiosyncratic (unpredictable) drug-induced liver injury is one of the most challenging liver disorders faced by hepatologists, because of the myriad of drugs used in clinical practice, available herbs and dietary supplements with hepatotoxic potential, the ability of the condition to present with a variety of clinical and pathological phenotypes and the current absence of specific biomarkers. This makes the diagnosis of drug-induced liver injury an uncertain process, requiring a high degree of awareness of the condition and the careful exclusion of alternative aetiologies of liver disease. Idiosyncratic hepatotoxicity can be severe, leading to a particularly serious variety of acute liver failure for which no effective therapy has yet been developed. These Clinical Practice Guidelines summarize the available evidence on risk factors, diagnosis, management and risk minimization strategies for drug-induced liver jury.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Drug-induced liver injury (DILI) is an uncommon adverse reaction to drugs, and other chemicals, including herbal and dietary supplements (HDS).”
From DILI Differences and Similarities between the US and Europe (2026) · cites this paper as [2]
In the citing paper
“The vast majority of cases of DILI occur at therapeutic doses in a small proportion of individuals exposed to the drug, representing an idiosyncratic reaction, and therefore unpredictable based on the drug's mechanism of action and related to the uniqueness of the individual [1,2].”
From DILI Differences and Similarities between the US and Europe (2026) · cites this paper as [2]
In the citing paper
“In pediatric medicine, DILI is a rare clinical situation. However, it has high morbidity and mortality, and it is one of the most common causes of acute liver failure. Furthermore, its diagnosis is clinically challenging due to its low incidence and phenotypic variability [6,7,8].”
From Metabolomic Analysis of Pediatric Patients with Idiosyncratic Drug-Induced Liver Injury According to the Updated RUCAM (2023) · cites this paper as [7]
In the citing paper
“The lack of a reliable diagnostic biomarker and evidence-based treatment paradigm has resulted in limited guidance on how to manage this aspect of DILI.”
From Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report (2023) · cites this paper as [2]
In the citing paper
“The lack of reliable diagnostic biomarkers and an evidence-based treatment paradigm has resulted in limited guidance on how to manage this aspect of DILI.2,25–27”
From Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report (2023) · cites this paper as [2]
In the citing paper
“However, drug rechallenge in DILI cases is potentially dangerous2,75 and is associated with risk of death or requirement for liver transplant.”
From Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report (2023) · cites this paper as [2]
In the citing paper
“Although there are some ambiguities regarding how to score certain sections as well as suboptimal reliability, RUCAM can provide systematic and framed guidance for the assessment of patients with suspected DILI and is the most widely used tool [26,27,51,59].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [26]
In the citing paper
“High TBil and ALP levels in the second month after an acute DILI episode and the biochemical nonresolution-6 model may help predict the risk of chronic injury and delayed recovery [26,72].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [26]
In the citing paper
“Although there are some ambiguities regarding how to score certain sections as well as suboptimal reliability, RUCAM can provide systematic and framed guidance for the assessment of patients with suspected DILI and is the most widely used tool [26,27,51,59].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [26]
In the citing paper
“Its potential value in confirming or excluding hepatocellular injury in cases of elevated ALT levels from a suspected extrahepatic origin (e.g., muscle) has been evaluated [26,175].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [26]
Citations
Cites
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Ekor, M. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00177 · Cited by 3,919
Alvarez, F., Berg, P. A., Bianchi, F. B., Bianchi, L., Burroughs, A. K., Cancado, E. L., Chapman, R. W., Cooksley, W. G. E., Czaja, A. J., Desmet, V. J., et al. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80297-9 · Cited by 2,903
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx225 · Cited by 2,367
Ostapowicz, G., Fontana, R. J., Schiødt, F. V., Larson, A., Davern, T. J., Han, S. H. B., McCashland, T. M., Shakil, A. O., Hay, J. E., Hynan, L., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-12-200212170-00007 · Cited by 2,227
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Michot, J. M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.016 · Cited by 2,127
Acetaminophen‐induced acute liver failure
Larson, A. M., Polson, J., Fontana, R. J., Davern, T. J., Lalani, E., Hynan, L. S., REISCH, J. S., Schiødt, F. V., Ostapowicz, G., Shakil, A. O., et al. (2005) · Hepatology · doi:10.1002/hep.20948 · Cited by 1,913
Simplified criteria for the diagnosis of autoimmune hepatitis
Hennes, E. M., Zeniya, M., Czaja, A. J., Parés, A., Dalekos, G. N., Krawitt, E. L., Bittencourt, P. L., Porta, G., Boberg, K. M., Hofer, H., et al. (2008) · Hepatology · doi:10.1002/hep.22322 · Cited by 1,901
Flagged first, then by citations
5 of the 371 references couldn’t be matched to a known paper.
Research works printed but not linked: 5
- Nicoletti, 2017, Genome-wide association study (GWAS) to identify genetic risk factors that increase susceptibility to antituberculosis drug-induced liver injury (ATDILI) [Abstract], Hepatology, 66, A-25
- Lim, 2008, Association of HLA-B*1502 allele and carbamazepine-induced severe adverse cutaneous drug reaction among Asians, a review, Neurol Asia, 13, 15
- US Food & Drug Administration, 2017, Drugs
- Sanjuan-Jimenez, 2017, Prevalence of hepatitis E markers in Spanish patients with suspected drug-induced liver injury [abstract], Hepatology, 66, 423A
- Fernández-Castañer, 2008, An analysis of the causes, characteristics, and consequences of reexposure to a drug or compound responsible for a hepatotoxicity event, Rev Esp Enfermedades Dig, 100, 278
Cited by
Sorted by citations
Items 601–700 of 1,278
Li, Y., Hu, Y., Meng, X., Thomson, P., Ouyang, D., Naisbitt, D. J., & Rao, T. (2025) · Archives of Toxicology · doi:10.1007/s00204-025-04171-4 · Cited by 4
Jiao, R., Wang, C.-Y., Ying, H., Nie, M., Leng, J., Liu, Y., Zhang, Z., Zhou, N., & Bai, C. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1679328 · Cited by 4
Antineoplastic drugs and drug-induced liver damage with cholestasis
Pereverzev, A. P., & Ostroumova, O. D. (2020) · Medical alphabet · doi:10.33667/2078-5631-2020-19-47-54 · Cited by 4
Plant extracts with putative hepatotoxicity activity
Saravanapriya, P., & Devi, K. P. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816488-4.00002-4 · Cited by 4
Wang, T., Yeh, M. M., Avigan, M., Pelosof, L. C., & Feldman, G. M. (2021) · The AAPS Journal · doi:10.1208/s12248-021-00629-2 · Cited by 4
RIPK1 in Liver Parenchymal Cells Limits Murine Hepatitis during Acute CCl4-Induced Liver Injury
Hameed, H., Farooq, M., Vuillier, C., Piquet‐Pellorce, C., Hamon, A., Dimanche‐Boitrel, M., Samson, M., & Seyec, J. L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137367 · Cited by 4
Drug-Induced Liver Injury from Herbal Liver Detoxification Tea
Niazi, B., Ahmed, K., Ahmed, M., Ali, S., Song, K., & Elias, S. (2022) · Case Reports in Gastroenterology · doi:10.1159/000526311 · Cited by 4
Hepatobiliary disease after bone marrow transplant: A cross‐sectional study of 377 patients
Dezan, M. G. F., Cavalcante, L. N., Silva, H. R. C., Almeida, A. D. M., de Assis, L. H. D. S., de Freitas, T. T., de Araujo, M. A. S., Cotrim, H. P., & Lyra, A. C. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17756 · Cited by 4
TAN, J., Zhou, P. Y., Chua, N. G. S., Hung, K. C., Lee, H. L. W., Lee, L. W., Lim, J. L., Lim, Y. C. S., Liew, Y., Loo, L. W., et al. (2024) · Clinical Therapeutics · doi:10.1016/j.clinthera.2024.05.007 · Cited by 4
Zhao, P., Yu, L., Ma, W., & Zhao, T. (2025) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s510973 · Cited by 4
Zhang, X., Zhang, L., Zhao, S., Dai, L., Li, H., Wu, X., Yan, H., Lin, R., & Zhu, K. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1529016 · Cited by 4
Steroids as rescue therapy for vitamin A-induced acute liver failure
Kulkarni, A. V., Kumar, P., Talukdar, R., & Rao, N. P. (2020) · BMJ Case Reports · doi:10.1136/bcr-2019-233902 · Cited by 4
Severe Persistent Jaundice after the Abuse of an Anabolic Androgenic Steroid Analogue
Goh, H. G., Lee, Y. J., & Kim, T. H. (2020) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2020.76.3.167 · Cited by 4
Acute hepatitis due to Olmesartan: an uncommon entity
de Célix, C. R., Serrano, R., & Garcı́a-Buey, L. (2020) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2020.7236/2020 · Cited by 4
Acute hepatocellular drug-induced liver injury probably caused by Doxazosin.
Sánchez, J. J., Díaz, L., & Crespo, J. J. M. (2020) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2020.7268/2020 · Cited by 4
Liu, X., Zhao, Y., Jia, G., Yang, F., Zhang, C., Han, B., Dai, J., Han, Y., Tang, B., Yang, X., et al. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14750 · Cited by 4
Daño hepático inducido por medicamentos: relación entre el índice R y la histopatología
Ardila-Suárez, O. M., Oriz-Benjumea, L., Arteta, A. A., & Guevara-Casallas, L. G. (2022) · Revista de Gastroenterología de México · doi:10.1016/j.rgmx.2021.03.008 · Cited by 4
Earnshaw, S., McDade, C. L., Bryan, A. B., Inês, M., Micallef, C., Sung, A., & Enoch, D. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.00425-22 · Cited by 4
Sun, X., Cui, Q., Ni, J., Liu, X., Zhu, J., Zhou, T., Huang, H., Ouyang, K., Wu, Y., & Yang, Z. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.00647-22 · Cited by 4
RetractedIberogast®-Induced Acute Liver Injury—A Case Report
Leroy, A., Perrin, H., Porret, R., Sempoux, C. L., Chtioui, H., Fraga, M., & Bart, P. (2022) · Gastro Hep Advances · doi:10.1016/j.gastha.2022.02.020 · Cited by 4
Patel, A. D., Pinsker, B. L., Wall, A., Arbogast, M., King, L. Y., & Sherzoy, S. (2022) · Clinical Liver Disease · doi:10.1002/cld.1230 · Cited by 4
Скрипник, І. М., Маслова, Г. С., Lymanets, T. V., & Skrypnyk, R. І. (2022) · Wiadomości Lekarskie · doi:10.36740/wlek202206114 · Cited by 4
Cao, L., Zhao, H., Qian, M., Shao, C., Zhang, Y., & Yang, J. (2022) · Journal of Biomaterials Science Polymer Edition · doi:10.1080/09205063.2022.2102715 · Cited by 4
Koya, J., Shen, T., Lu, G., Gauthier, A. G., Mantell, L. L., Ashby, C. R., & Reznik, S. E. (2022) · Fortune Journal of Health Sciences · doi:10.26502/fjhs.076 · Cited by 4
Liu, Z., Liang, S., Wei, X., Du, X., & Zhang, J. (2022) · BMC Gastroenterology · doi:10.1186/s12876-022-02523-3 · Cited by 4
Tonutti, A., Simonetta, E., Stainer, A., Suigo, G., Santis, M. D., Selmi, C. F., Masetti, C., Lleò, A., Terracciano, L., Aliberti, S., et al. (2023) · Modern Rheumatology Case Reports · doi:10.1093/mrcr/rxad005 · Cited by 4
Sentilhes, L., Sénat, M., Bouchghoul, H., Delorme, P., Gallot, D., Garabédian, C., Madar, H., Sananès, N., Perrotin, F., & Schmitz, T. (2023) · Gynécologie Obstétrique Fertilité & Sénologie · doi:10.1016/j.gofs.2023.09.004 · Cited by 4
Deng, L., Zhang, Y., & Sun, H. (2024) · Medicine · doi:10.1097/md.0000000000037456 · Cited by 4
Pinazo-Bandera, J. M., García‐Cortés, M., & Andrade, R. J. (2023) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-23-319 · Cited by 4
Self-citationEmerging Pathogens Causing Acute Hepatitis
Sayed, I. M., El‐Shamy, A., & Abdelwahab, S. F. (2023) · Microorganisms · doi:10.3390/microorganisms11122952 · Cited by 4
Namoju, R., & Chilaka, K. N. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03036-4 · Cited by 3
Guidelines for safe use of Polygoni Multiflori Radix
Xiao, X., Wang, J., Song, H., Ouyang, D., Zou, Z., Wang, R., He, T., Jing, J., Guo, Y., Bai, Z., et al. (2024) · Acupuncture and Herbal Medicine · doi:10.1097/hm9.0000000000000113 · Cited by 3
Propafenone-Induced Cholestatic Liver Injury: When Diagnosis Does Not Skip a Beat
Ferreira, A. I., Silva, V. M., Arieira, C., Xavier, S. A., Magalhães, J. T., & Cotter, J. B. (2024) · GE Portuguese Journal of Gastroenterology · doi:10.1159/000541557 · Cited by 3
Liver protection of CACA technical guidelines for holistic integrative management of cancer
Zhang, N., Lu, L., Cao, B., Gao, Y., Han, F., Li, L., Li, Q., Li, S., Li, X., Liu, J., et al. (2025) · Holistic Integrative Oncology · doi:10.1007/s44178-025-00157-5 · Cited by 3
Lin, M., Xie, Y., Wu, J., Zhang, C., Shi, S., Lin, N., Tong, X., & Li, Y. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70228 · Cited by 3
Unveiling the hidden risk: Herbal and dietary supplement consumption in liver disease patients
Canga, E., Pocurull, A., Rodríguez-Reyes, M., Collazos, C., Martín, L., Mariñó, Z., Lens, S., & Forns, X. (2025) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastrohep.2025.502520 · Cited by 3
Cao, R., Zhang, S., Zhang, J., Zhao, Y., Zhang, X., & Guo, Z. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1657332 · Cited by 3
Fan, Y., Zheng, J., Gu, J., & Li, L. (2025) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-025-01051-6 · Cited by 3
Fettiplace, A., Regev, A., Kiazand, A., Heinzel-Pleines, U., Bahjat, M., Garg, A., Kikuchi, L., Li, H., Hamidi, A., Alpers, D., et al. (2025) · Drug Safety · doi:10.1007/s40264-025-01635-5 · Cited by 3
Self-citationCao, Q., chen, S., Zhang, Y., Yang, J., & Wang, Z. (2026) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2026.102763 · Cited by 3
Bejarano, I., Jiménez‐Jorge, S., Lobo-Acosta, M. Á., López, A. I. Á., Rosso-Fernández, C. M., Ruiz, R. L., Eichau, S., Ruíz-Peña, J. L., Geniz, M. A., Ampuero, J., et al. (2026) · CNS Drugs · doi:10.1007/s40263-025-01261-w · Cited by 3
Beyond the Pump: The Evolving Molecular Landscape of Intrahepatic Cholestasis
Ziccardi, Zorzi, M., & D’Adamo, P. (2026) · Diagnostics · doi:10.3390/diagnostics16050726 · Cited by 3
Holmstroem, R. B., Teisner, A., Sweep, M. W. D., Noringriis, I. M., Khan, S., Aagaard, N. K., Karlström, J., Jurlander, R. S., Sohlin, J. E., Monberg, T. J., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013861 · Cited by 3
Gu, J., Wang, Y., Wang, X., Yan, Y., Pei, F., He, T., Zhang, C., Li, J., & Wang, W. (2026) · Liver International · doi:10.1111/liv.70578 · Cited by 3
Liver Safety of the Dual Neurokinin-1/-3 Receptor Antagonist Elinzanetant
Lewis, J. H., Andrade, R. J., Larrey, D. G., Horsmans, Y., Anderson, R. A., Trajanovic, M., Groettrup‐Wolfers, E., & Zuurman, L. (2026) · Drug Safety · doi:10.1007/s40264-026-01663-9 · Cited by 3
Self-citationLi, X., Dai, C., Chen, X., Lv, X., Wang, X., Li, L., Xu, J., Jia, G., Zhang, J., Su, D., et al. (2026) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2026.139951 · Cited by 3
Molnár, D., Reznik, E., & Porrogi, P. (2026) · Pharmaceuticals · doi:10.3390/ph19050733 · Cited by 3
Gastroenterologische Komplikationen der neuen Immuncheckpoint-Inhibitor-Therapien
Götze, J., Bitzer, M., & Malek, N. P. (2019) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-0848-9965 · Cited by 3
Experience of Using Remdesivir in Patients with Novel Coronavirus Infection
Petrov, V. I., Ryazanova, A. Y., Privaltseva, N. S., & Nekrasov, D. A. (2022) · Safety and Risk of Pharmacotherapy · doi:10.30895/2312-7821-2022-10-4-365-380 · Cited by 3
Sun, X., Cui, Q., Ni, J., Liu, X., Zhu, J., Zhou, T., Huang, H., Ouyang, K., Wu, Y., & Yang, Z. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.04715-22 · Cited by 3
Liver Pathology After Hematopoietic Stem Cell Transplantation
Phansalkar, R., Kambham, N., & Charu, V. (2023) · Surgical pathology clinics · doi:10.1016/j.path.2023.04.007 · Cited by 3
Tajudeen, O. Y. T., Salisu, T. F., Oladele, E. O., Yaro, C. A., Iliyazu, N., Tukur, A., Izuafa, A., & Yari, M. A. (2023) · Maǧallaẗ ǧāmiʿaẗ al-Sulṭān Qābūs li-l-ʿulūm/Sultan Qaboos University journal for science · doi:10.53539/squjs.vol28iss1pp1-9 · Cited by 3
Qian, W., Li, L., Zeng, X., Yin, J., & Guo, J. (2023) · Exploration of Digestive Diseases · doi:10.37349/edd.2023.00021 · Cited by 3
Lin, D. S., Tzeng, S., Cha, T., Hung, C.-M., Lin, W., Yang, C., Lu, H.-Y., Chang, J., & Huang, S.-W. (2023) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2023.08.001 · Cited by 3
Increased aminotransferases do not necessarily mean hepatotoxicity of CFTR modulator therapy
Woynarowski, M., Sapiejka, E., Jóźwiak, M., & Wierzbicka, A. (2023) · Clinical and Experimental Hepatology · doi:10.5114/ceh.2023.132264 · Cited by 3
Mao, T., He, P., Xu, Z., Lai, Y., Huang, J., Yu, Z., Li, P., & Gong, X. (2024) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2024.116023 · Cited by 3
Severe liver injury induced by minocycline in hepatitis B patient: a Case Report
Wang, R., Li, C., & Xue, X. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1516217 · Cited by 3
Sun, Y., Wang, R., Wang, C., Shao, X., Zheng, X., Li, H., Chi, Y., Deng, B., Li, Y., Jin, S., et al. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1492002 · Cited by 3
Azaphenothiazine Conjugates: A New Class of Antimicrobial Compounds
Kushwaha, K., Buchanan, D., Nkosi, A. K., Jangra, J., Kumar, R., Singh, S. K., Jain, S. C., & Panda, S. S. (2025) · Chemistry & Biodiversity · doi:10.1002/cbdv.202403338 · Cited by 3
To use or not to use: Safety of selected painkillers in patients with chronic liver diseases
Rorat, M., Szymański, W., & Zińczuk, A. (2025) · Clinical and Experimental Hepatology · doi:10.5114/ceh.2025.151745 · Cited by 3
Ali, A. S. M., Wu, D., Roehrs, V., Nguyen, D. B. T., Ziersch, M., Braeuning, A., & Kurreck, J. (2025) · Biofabrication · doi:10.1088/1758-5090/ae1063 · Cited by 3
Ueno, A., Ueno, M., Nishikawa, M., Karai, M., Imai, S., Kayahara, T., Takabatake, H., Morimoto, Y., & Yamaguchi, K. (2025) · Hepatology Research · doi:10.1111/hepr.70059 · Cited by 3
Anti-Tuberculosis Drug Induced Liver Injury and Ursodeoxycholic Acid
Lang, S. M., Al-Nemnem, E., & Schiffl, H. (2020) · Journal of Tuberculosis Research · doi:10.4236/jtr.2020.82007 · Cited by 3
Han, Y., Zhuang, Y., Tang, W., Chen, L., Chen, Y., Gong, Q., & Zhang, X. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.9887 · Cited by 3
Croatian guidelines for the diagnosis and treatment of nonalcoholic fatty liver disease
Jukić, L. V. (2021) · Acta Clinica Croatica · doi:10.20471/acc.2021.60.s1.03 · Cited by 3
Bustíos, C., Úmeres, J. S., Asato-Higa, C., & Zapata, V. M. (2021) · Revista de Gastroenterología del Perú · doi:10.47892/rgp.2021.412.1280 · Cited by 3
Paz, M. V., Niu, H., Segovia‐Zafra, A., Medina‐Cáliz, I., Sanabria‐Cabrera, J., Lucena, M. I., Andrade, R. J., & Álvarez‐Álvarez, I. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10225317 · Cited by 3
Self-citationDrug-induced liver injury: Relation between the R ratio and histopathology
Ardila-Suárez, O. M., Oriz-Benjumea, L., Arteta, A. A., & Guevara-Casallas, L. G. (2022) · Revista de Gastroenterología de México (English Edition) · doi:10.1016/j.rgmxen.2022.03.006 · Cited by 3
Severe Drug-Induced Liver Injury From Over-the-Counter Medication
Satoh, K., Okuyama, M., Hirasawa, N., & Nakae, H. (2023) · Cureus · doi:10.7759/cureus.33558 · Cited by 3
Advances in the management of idiosyncratic drug-induced liver injury
Memon, A., Yeboah‐Korang, A., & Fontana, R. J. (2023) · Clinical Liver Disease · doi:10.1097/cld.0000000000000052 · Cited by 3
Hwang, D., Seo, Y., Lee, E., Won, D., Kim, C., Kang, M., Jeon, Y., Kim, H., Park, J. W., & Yun, J.-W. (2023) · Food and Chemical Toxicology · doi:10.1016/j.fct.2023.113890 · Cited by 3
ILIESCU, D. (2023) · FARMACIA · doi:10.31925/farmacia.2023.3.11 · Cited by 3
Cyclopia intermedia E. Mey protects against ROS-induced liver injury in HepG2/C3A cells.
Reddy, S., Rashed, K. N. Z., Marnewick, J. L., Rautenbach, F., Koekemoer, T., & van de Venter, M. (2023) · South African Journal of Botany · doi:10.1016/j.sajb.2023.09.048 · Cited by 3
Shu, Y.-Y., Hu, L., Yang, L., Chu, H., Ye, J., & Jin, Y. T. (2023) · Current Medical Science · doi:10.1007/s11596-023-2801-y · Cited by 3
Giunta, D. H., Karlsson, P., Younus, M., Berglind, I. A., Kieler, H., & Reutfors, J. (2024) · BMC Gastroenterology · doi:10.1186/s12876-023-03110-w · Cited by 3
Riveiro‐Barciela, M., Carballal, S., Díaz‐González, Á., Mañosa, M., Plazas, J. G., Cubiella, J., Jiménez‐Fonseca, P., Varela, M., Menchen, L. A., Sangro, B., et al. (2024) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2024.10250/2024 · Cited by 3
Eldredge, J. A., Pittet, L. F., & Gwee, A. (2024) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkae009 · Cited by 3
Antonios, K., Shaheen, A., Dutta, P., & Fine, M. (2024) · Cureus · doi:10.7759/cureus.55717 · Cited by 3
Rovira, A. R. I., Cattley, R. C., & Brown, D. L. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-821046-8.00010-4 · Cited by 3
Immune-mediated hepatitis: Basic concepts and treatment
Velasco, J. A. V.-R., Calderón, D. K. T., Cerpa‐Cruz, S., Chávez, J. A. V., Martínez, J. F. U., García-Jiménez, E. S., Ledesma, J. M. A., Díaz‐González, Á., & Crespo, J. (2024) · Revista de Gastroenterología de México (English Edition) · doi:10.1016/j.rgmxen.2023.12.001 · Cited by 3
Salsabila, A., Kholili, U., & Novida, H. (2023) · Bali Medical Journal · doi:10.15562/bmj.v12i2.4206 · Cited by 3
Woynarowski, M., Sapiejka, E., Jóźwiak, M., Milczewska, J., Zybert, K., Krusiński, A., Siwiec, J., & Wierzbicka, A. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e31189 · Cited by 3
Riveiro‐Barciela, M., Carballal, S., Díaz‐González, Á., Mañosa, M., Gallego-Plazas, J., Cubiella, J., Jiménez‐Fonseca, P., Varela, M., Menchen, L. A., Sangro, B., et al. (2024) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2023.10.003 · Cited by 3
Chai, L., Wang, R., Teschke, R., Jin, S., Deng, J., & Qi, X. (2024) · Medicine · doi:10.1097/md.0000000000039439 · Cited by 3
Badary, H. A., Hashem, M. B., & El‐Kassas, M. (2024) · Egyptian Liver Journal · doi:10.1186/s43066-024-00381-0 · Cited by 3
Wang, J.-L., Jiang, S., Hu, A., Shi, X., Zhou, A.-W., Lin, K. Y., Fan, Y., Jin, M., & Zhang, H. (2024) · Clinica Chimica Acta · doi:10.1016/j.cca.2024.120085 · Cited by 3
Zhai, X., He, X., Huang, A., Liu, Z., Chen, S., Chang, B., Zhu, Y., Xie, H., Bai, Z., Xiao, X., et al. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16876 · Cited by 3
Xu, Y., Shi, J., Mok, H. L., Lyu, C., Chen, J., Huang, C., Qin, H., Lin, C., Tan, H., & Bian, Z. (2025) · Advanced Science · doi:10.1002/advs.202502993 · Cited by 3
Liu, Z., Yuan, D., Chang, J., Shi, L., Li, J., Zhao, M., & Yang, Q. (2025) · Current Oncology · doi:10.3390/curroncol32070393 · Cited by 3
Serras, A. S., Cipriano, M., Silva, P. M. D. G., & Miranda, J. P. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.91794 · Cited by 3
Rechallenge of voriconazole successfully tolerated after hepatic toxicity
Narumoto, O., Suzuki, J., Takeda, K., Tamura, A., Nagai, H., & Matsui, H. (2020) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2020.101191 · Cited by 3
Hepatic manifestations of drug reaction with eosinophilia and systemic symptoms syndrome
Delgado, M., Casu, S., Montani, M., Brunner, F., Semmo, N., Berzigotti, A., & Dufour, J. (2021) · Exploration of Medicine · doi:10.37349/emed.2021.00037 · Cited by 3
Hung, H.-Y., Chen, C., & Liao, Y.-H. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.640317 · Cited by 3
A Rare Case of Drug Induced Liver Injury Secondary to Empagliflozin
Nunes, A. L., Santos, D., Figueiredo, C., Ferreira, D., Lima, J., & Santos, A. (2021) · Medicina Interna · doi:10.24950/rspmi.cc.131.4.2021 · Cited by 3
Tong, D., Wang, Y., Ma, J., Wang, J., & Li, J. (2024) · Studies in health technology and informatics · doi:10.3233/shti230979 · Cited by 2
Chung, M. S. H., Wong, C. K. H., Li, X., Lai, F. T. T., Wan, E. Y. F., Chui, C. S. L., Cheng, F. W. T., Chan, E. W., Cheung, C., Xiong, X., et al. (2024) · Liver international communications. · doi:10.1002/lci2.84 · Cited by 2
Labban, H., Kwait, B., Paracha, A., Islam, M., & Kim, D. O. (2024) · Cureus · doi:10.7759/cureus.69601 · Cited by 2
Hinojo, C., Cantos, B., Antolín, S., Arqueros, C., Díaz-Redondo, T., González, I., Llabrés, E., Ramírez, J. A., Barral, M., Escudero, M., et al. (2024) · Clinical Breast Cancer · doi:10.1016/j.clbc.2024.12.016 · Cited by 2
Chiaka-Onyemeze, N. H., Nkwocha, C. C., Edeke, A. A., & Ezeako, E. C. (2025) · International Journal of Plant Based Pharmaceuticals · doi:10.62313/ijpbp.2025.250 · Cited by 2
Metadata
- Authors
- Andrade, R. J., Aithal, G. P., Björnsson, E. S., Kaplowitz, N., Kullak-Ublick, G. A., Larrey, D., & Karlsen, T. H.
- ORCID
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2019-06
- Volume
- 70
- Issue
- 6
- Pages
- 1222-1261
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2924328881
- Semantic Scholar
- 6d774d1c570eef200451a1e8a8f5655c367a4eaf
- Cited by
- 1,276
- References
- 371
- Citations by year
- 2026: 243 · 2025: 211 · 2024: 175 · 2023: 159 · 2022: 158 · 2021: 184 · 2020: 117 · 2019: 27
- FWCI
- 78.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- European Cooperation in Science & Technology
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- drug-induced liver injury, idiosyncratic drug-induced liver injury, hepatotoxicity, acute liver failure, risk factors, diagnosis, risk minimization
- MeSH terms
- Adult, Aged, Fatty Liver, Female, Histocompatibility Testing, Humans, Liver Neoplasms, Male, Middle Aged, Mitochondria, Risk Factors, Chemical and Drug Induced Liver Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
